Citeline

Explore expert articles from our top publications in the newest issue of our free newsletter: Citeline Editors' Picks. In this issue we are covering Rare Disease Day, the future of US life sciences, animal testing, and more!    Subscribe today for expert analysis on pharma, medtech, and consumer health.

We're thrilled to attend CDMO Live, happening May 7-8, 2025: https://ow.ly/UjtQ50VajRG. This is an exclusive event bringing together the sharpest minds in biopharma outsourcing. Meet Roberta Ricciotti at the event and be sure to register now! https://ow.ly/F7Mh50VajRH.

Pharma’s biggest trends are here: https://ow.ly/ysOg50VjYbO. The 33rd annual Pharma R&D Review covers it all—pipeline shifts by company, therapeutic area, and drug type. Whether you're monitoring competitors or planning your next move, this report has the insights you need.
 Get the full report now: https://ow.ly/ysOg50VjYbO #RD25 _____ Follow Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.

There is still an unmet need for new and different obesity therapeutic interventions: https://ow.ly/Th0k50VeUNo. Tim Blackstock, Citeline's Cardiovascular and Metabolic & Infectious Diseases Therapy Area Director, comments in a recent BioXconomy article on the AbbVie/Gubra deal. Read the full article: https://ow.ly/Th0k50VeUNo. #Ozempic #Wegovy #Mounjaro _____ Follow Citeline, the leading provider of drug, device, company, clinical trial, and market intelligence in the pharmaceutical and medtech markets.

China has started appearing as the key player in the clinical trial landscape globally in terms of the growing number of global clinical trials initiated in the country. https://ow.ly/PJCZ50UkfBt Janelle Hart, Managing Editor, Custom Content at Citeline, a Norstella company, sits down with Xu Hu and Jie (Dexter) Yan, senior APAC reporters at Citeline, to discuss key trends and ongoing barriers impacting drug development in China and the future Chinese pharma market. Click the link in this post for access to the full article. #ClinicalTrials #ChinaBiotech #APACPharma #BiotechTrends #PharmaceuticalResearch

Norstella, Citeline's parent company, has been named to Fast Company's list of the World’s Most Innovative Companies for 2025!

Enter today! The Global Generics & Biosimilars Awards 2025 features categories celebrating diverse achievements across the global off-patent pharmaceutical industry such as: • Biosimilar Initiative of the Year: Recognizing initiatives driving biosimilar adoption, from development to market success. • Leader of the Year: Honoring senior leaders in generics and biosimilars for strategic vision, growth, and industry impact. • Industry Partner of the Year: Recognizing excellence among firms and individuals supporting generics and biosimilars industries. Does your company fit these descriptions? Submit your entries today! Entries close: Friday, 1 August, 2025 https://ow.ly/AMaB50V9tYb #GGBAwards #AwardCategories #OffPatent

Come see us at #BIOEuropeSpring booth #78!

🏆 The countdown to the Citeline Awards 2025 is on! This is your chance to be part of one of the most prestigious nights in the industry! Book your table now and celebrate excellence with the best in the business. 🎉Early-bird discount ends this Friday, March 21! Don’t miss out on this exclusive offer—secure your spot and give your team the recognition they truly deserve. Reserve your table today! https://ow.ly/w2iF50VjLcn #CitelineAwards

Reflections on AAD 2025: Key Takeaways from Orlando AAD 2025 just wrapped up under the beautiful Orlando sunshine, bringing together nearly 18,000 attendees for one of the most important dermatology conferences of the year. Here are some key highlights that stood out: ✅ GLP-1 Agonists & Systemic Treatments in Psoriasis There’s growing interest in the role of weight control via GLP-1 agonists in improving responses to systemic treatments for severe psoriasis. Ongoing clinical trials will provide more insights into this potential synergy. ✅ Icotrokinra: A Game Changer? As an oral IL-23R antagonist, Icotrokinra could shake up the psoriasis treatment landscape, which is currently dominated by injectables. ✅ Atopic Dermatitis: A Highly Heterogeneous Disease Different patient profiles call for tailored treatments. While anti-IL-31R Nemluvio targets itch, other options, such as anti-IL-4/13, anti-IL-13, and JAK inhibitors, focus on treating erythematous skin in different patient populations. ✅ Novel targets for Atopic Dermatitis: Anti-OX40 therapies Emerging anti-OX40 therapies (rocatinlimab and amlitelimab) are in fierce competition. Phase 3 topline data for anti-OX40 agents are expected in 2026, with potential for sustained efficacy months after treatment withdrawal. ✅ JAK Inhibitors: Balancing Risk & Benefit Despite ongoing debates around cardiovascular and malignancy risks, some dermatologists advocate for JAK inhibitors (oral & topical) in psoriasis, atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, and alopecia areata. Some clinicians are even combining oral JAK inhibitors with biologics for a rapid skin clearance, followed by a tapering strategy, as mentioned in an offline discussion. ✅ Alopecia Areata: The Importance of Early Treatment Experts emphasized that early intervention leads to better treatment outcomes for alopecia areata, reinforcing the need for timely diagnosis and management. ✅ Biologic Boom & Women’s Health With biologics transforming dermatology, there’s a pressing need for more research on their safety in pregnant and breastfeeding patients, given that a significant portion of dermatology patients are women of childbearing age. As dermatology continues to evolve, these insights from AAD 2025 highlight the need for personalized, data-driven, and patient-centered approaches. Exciting times ahead for dermatology innovation! #AAD2025 #Dermatology #Psoriasis #AtopicDermatitis #Biologics #JAKinhibitors